ImmunityBio starts European ANKTIVA treatments in Germany and Austria
ImmunityBio said on November 4 that patients in Germany and Austria had begun receiving ANKTIVA with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The treatment follows the European Commission's conditional authorization in February 2026. Accord Healthcare is handling commercial and market-access support, while Uniphar is providing logistics and distribution services.
Why it matters
The announcement marks the start of patient access in Europe and gives ImmunityBio a commercial pathway for ANKTIVA in the authorized markets. Accord Healthcare and Uniphar's roles support market access, supply and distribution for the launch.
Key facts
- 1The initial treatments were given in Germany and Austria to patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. finanznachrichten.de
- 2The European Commission's conditional authorization, granted in February 2026, covers all 27 European Union member states plus Iceland, Norway and Liechtenstein. finanznachrichten.de
- 3Accord Healthcare is providing commercial and market-access assistance, while Uniphar is supplying order-to-cash, storage, distribution, importation and quality-support services. finanznachrichten.de
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.